

Maria Buti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2745433/maria-buti-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

373
papers

23,880
citations

64
h-index

148
g-index

427
ext. papers

28,870
ext. citations

6.5
avg, IF

7.21
L-index

#	Paper	IF	Citations
373	Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B.. <i>JHEP Reports</i> , 2022 , 4, 100449	10.3	0
372	Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection.. <i>JHEP Reports</i> , 2022 , 4, 100388	10.3	3
371	Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up.. <i>Microbiology Spectrum</i> , 2022 , e0214921	8.9	
370	The impact of COVID-19 on the cascade of care of HCV in the US and China.. <i>Annals of Hepatology</i> , 2022 , 100685	3.1	1
369	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 , 7, 396-415	18.8	11
368	Hepatitis B Virus Variants with Multiple Insertions and/or Deletions in the X Open Reading Frame 3' End: Common Members of Viral Quasispecies in Chronic Hepatitis B Patients. <i>Biomedicines</i> , 2022 , 10, 1194	4.8	1
367	Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review.. <i>Scientific Reports</i> , 2021 , 11, 24133	4.9	2
366	Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 733-744	6.1	2
365	Cross-sectional evaluation of circulating hepatitis B virus RNA and DNA: Different quasispecies?. <i>World Journal of Gastroenterology</i> , 2021 , 27, 7144-7158	5.6	0
364	Letter to the Editor: standardization of HBV RNA assay for the different phases of chronic hepatitis B is essential. <i>Hepatology</i> , 2021 ,	11.2	1
363	The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , 2021 ,	40	12
362	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2021 ,	13.4	5
361	Eliminating hepatitis C on the Balearic Islands, Spain: a protocol for an intervention study to test and link people who use drugs to treatment and care. <i>BMJ Open</i> , 2021 , 11, e053394	3	
360	Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1319-1324	3.4	2
359	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality 2021 ,		5
358	EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. <i>Journal of Hepatology</i> , 2021 , 74, 944-951	13.4	61
357	Next-generation sequencing for the diagnosis of hepatitis B: current status and future prospects. <i>Expert Review of Molecular Diagnostics</i> , 2021 , 21, 381-396	3.8	3

356	Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. <i>Liver International</i> , 2021 , 41, 1922-1932	7.9	5
355	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021 , 224, 1890-1899	7	4
354	Impact of the COVID-19 pandemic on HCV elimination in Spain. <i>Journal of Hepatology</i> , 2021 , 74, 1246-1248	4.4	6
353	Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1177-1189	3.4	2
352	One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 462-469	6.1	4
351	Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B. <i>JHEP Reports</i> , 2021 , 3, 100280	10.3	0
350	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021 , 3, 100290	10.3	0
349	Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide. <i>Liver International</i> , 2021 , 41 Suppl 1, 9-14	7.9	1
348	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	9
347	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 46-60.e8	6.9	15
346	Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase. <i>Hepatology</i> , 2021 , 73, 1652-1670	11.2	4
345	Etiologies and Features of Acute Viral Hepatitis in Spain. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1030-1037	6.9	2
344	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 12-19	3.4	12
343	Reflex viral load testing in dried blood spots generated by plasma separation card allows the screening and diagnosis of chronic viral hepatitis. <i>Journal of Virological Methods</i> , 2021 , 289, 114039	2.6	5
342	Sophisticated viral quasispecies with a genotype-related pattern of mutations in the hepatitis B X gene of HBeAg-ve chronically infected patients. <i>Scientific Reports</i> , 2021 , 11, 4215	4.9	1
341	The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries. <i>Liver International</i> , 2021 , 41, 934-948	7.9	6
340	Utility of the Cobas Plasma Separation Card as a Sample Collection Device for Serological and Virological Diagnosis of Hepatitis C Virus Infection. <i>Diagnostics</i> , 2021 , 11,	3.8	1
339	2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 583-605	6.1	4

338	Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study. <i>World Journal of Gastroenterology</i> , 2021 , 27, 5112-5125	5.6	1
337	A novel model of care for simplified testing of HBV in African communities during the COVID-19 pandemic in Spain. <i>Scientific Reports</i> , 2021 , 11, 17063	4.9	1
336	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	1
335	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	15
334	Anti-epileptic drugs and hepatitis C therapy: Real-world experience. <i>Journal of Hepatology</i> , 2021 , 75, 984-985	13.4	0
333	Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy. <i>Clinics in Liver Disease</i> , 2021 , 25, 725-740	4.6	1
332	Overview of Treatment Recommendations and Pretreatment Assessment 2021 , 33-42		
331	Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. <i>Therapeutic Advances in Infectious Disease</i> , 2021 , 8, 2049936120985954	2.8	5
330	Barriers to linkage to care in hepatitis C patients with substance use disorders and dual diagnoses, despite centralized management. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211016563	4.7	1
329	Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials. <i>Journal of Hepatology</i> , 2020 , 73, S883-S885	13.4	2
328	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	17
327	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020 , 73, 1037-1045	13.4	34
326	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020 , 383, 1522-1534	59.2	913
325	Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 500-512	6.1	3
324	Anti-HBc impacts on the risk of hepatitis B reactivation but not on survival of solid-organ transplant recipients. <i>Medicine (United States)</i> , 2020 , 99, e19407	1.8	3
323	An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disorders. <i>Scientific Reports</i> , 2020 , 10, 3038	4.9	2
322	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 441-453	18.8	45
321	Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues. <i>Liver International</i> , 2020 , 40 Suppl 1, 15-21	7.9	10

320	Unexpected long-lasting anti-HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis?. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 747-753	3.4	11
319	Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 1570-1578	4	7
318	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020 , 72, 1088-1096	13.4	50
317	JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. <i>Gastroenterology</i> , 2020 , 159, 521-533.e9	13.3	33
316	Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors. <i>Liver International</i> , 2020 , 40, 1906-1916	7.9	20
315	hbsag levels can be used to rule out cirrhosis in hbeag positive chronic hepatitis b: results from the sonic-b study. <i>Journal of Infectious Diseases</i> , 2020 ,	7	5
314	Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1399-1406	6.1	5
313	Rethinking the inactive carrier state: management of patients with low-replicative HBeAg-negative chronic hepatitis B and normal liver enzymes 2020 , 150-155		
312	Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020 , 43, 559-587	0.1	0
311	Is the universal population Hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence. <i>Revista Espanola De Quimioterapia</i> , 2020 , 33, 240-248	1.6	4
310	Conservation and variability of hepatitis B core at different chronic hepatitis stages. <i>World Journal of Gastroenterology</i> , 2020 , 26, 2584-2598	5.6	4
309	Principles for implementing a population screening strategy for hepatitis C in Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 64-70	0.9	2
308	Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial. <i>Journal of Hepatology</i> , 2020 , 72, 441-449	13.4	60
307	Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 158-166	6.1	12
306	Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. <i>Hepatology Communications</i> , 2020 , 4, 8-20	6	18
305	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020 , 174, 104694	10.8	20
304	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020 , 72, 539-557	13.4	88
303	Role of Biomarkers in Guiding Cure of Viral Hepatitis B. <i>Seminars in Liver Disease</i> , 2020 , 40, 49-60	7.3	3

302	Amino Acid Substitutions Associated with Treatment Failure for Hepatitis C Virus Infection. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.7	9
301	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020 , 73, 1368-1378	13.4	41
300	GEHEP 010 study: Prevalence and distribution of hepatitis B virus genotypes in Spain (2000-2016). <i>Journal of Infection</i> , 2020 , 81, 600-606	18.9	2
299	Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide. <i>Digestive and Liver Disease</i> , 2020 , 52, 1164-1169	3.3	6
298	Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 559-587	0.9	6
297	Targeted long read sequencing reveals the comprehensive architecture and expression patterns of integrated HBV DNA in CHB liver biopsies. <i>Journal of Hepatology</i> , 2020 , 73, S6-S7	13.4	3
296	A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results. <i>Journal of Hepatology</i> , 2020 , 73, S67-S68	13.4	2
295	Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data. <i>Journal of Hepatology</i> , 2020 , 73, S129-S130	13.4	13
294	Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. <i>Journal of Hepatology</i> , 2020 , 72, 472-480	13.4	79
293	COVID-19 and hepatitis B infection. <i>Antiviral Therapy</i> , 2020 , 25, 389-397	1.6	5
292	JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1. <i>Hepatology</i> , 2019 , 69, 2349-2363	11.2	5
291	Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 267-271	2.2	6
290	Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. <i>Journal of Hepatology</i> , 2019 , 71, 666-672	13.4	35
289	Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. <i>Liver International</i> , 2019 , 39, 1868-1875	7.9	51
288	Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180mg and uprifosbuvir 450mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1127-1138	3.4	3
287	Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity. <i>Annals of Hepatology</i> , 2019 , 18, 215-219	3.1	3
286	Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 296-304	18.8	16
285	Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8 T Cells and Evolve at the Population Level. <i>Gastroenterology</i> , 2019 , 156, 1820-1833	13.3	23

284	Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 538-544	18.8	29
283	Too many people with viral hepatitis are diagnosed late - with dire consequences. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 451-452	24.2	19
282	Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. <i>Scientific Reports</i> , 2019 , 9, 10529	4.9	7
281	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019 , 42, 579-592	0.1	2
280	Characterization of hepatitis B virus X gene quasispecies complexity in mono-infection and hepatitis delta virus superinfection. <i>World Journal of Gastroenterology</i> , 2019 , 25, 1566-1579	5.6	3
279	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 862-873	0.9	4
278	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 579-592	0.9	13
277	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2019 , 71, 1070	11.2	23
276	Factors influencing hepatitis C cure in the era of direct-acting antivirals. <i>Gastroenterología Y Hepatología</i> , 2019 , 42 Suppl 1, 1-7	0.9	1
275	Viral Load Measurements in Individuals with Hepatitis C Virus Infection: on the European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Clinical Microbiology</i> , 2019 , 58,	9.7	3
274	Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: a systematic literature review and meta-analysis. <i>Quality of Life Research</i> , 2019 , 28, 297-319	3.7	10
273	Decompensated Liver Disease due to Primary Hepatic Amyloidosis: Is Liver Transplantation Still Mandatory?. <i>Hepatology</i> , 2019 , 69, 2701-2703	11.2	0
272	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019 , 70, 1008-1015	13.4	40
271	Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?. <i>Journal of Hepatology</i> , 2019 , 70, 564-566	13.4	27
270	Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2019 , 156, 635-646.e9	13.3	86
269	Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1278-1287	6.1	39
268	Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8 T Cells. <i>Journal of Virology</i> , 2018 , 92,	6.6	14
267	ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B. <i>Liver International</i> , 2018 , 38, 1760-1769	7.9	15

266	96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , 2018 , 68, 672-681	13.4	180
265	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018 , 68, 1129-1136	13.4	64
264	Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. <i>Liver International</i> , 2018 , 38 Suppl 1, 84-89	7.9	23
263	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. <i>Journal of Hepatology</i> , 2018 , 68, 940-948	13.4	12
262	Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. <i>Gastroenterology</i> , 2018 , 154, 976-988.e4	13.3	102
261	Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation. <i>Liver International</i> , 2018 , 38, 1940-1950	7.9	10
260	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 383-403	18.8	702
259	Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). <i>Liver International</i> , 2018 , 38, 842-850	7.9	41
258	HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 114-122	6.1	3
257	Quantitative characterization of hepatitis delta virus genome edition by next-generation sequencing. <i>Virus Research</i> , 2018 , 243, 52-59	6.4	8
256	Hepatitis B virus: The challenge of an ancient virus with multiple faces and a remarkable replication strategy. <i>Antiviral Research</i> , 2018 , 158, 34-44	10.8	21
255	Letter: direct-acting anti-viral (DAA) therapy needs strong safety and efficacy check-authors reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 235-236	6.1	
254	No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	27
253	Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 3487-3497	4	28
252	Analysis of hepatitis B virus preS1 variability and prevalence of the rs2296651 polymorphism in a Spanish population. <i>World Journal of Gastroenterology</i> , 2018 , 24, 680-692	5.6	8
251	New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors. <i>Journal of General Virology</i> , 2018 , 99, 97-102	4.9	6
250	Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. <i>Hepatology</i> , 2018 , 67, 1253-1260	11.2	97
249	Detection of hyper-conserved regions in hepatitis B virus X gene potentially useful for gene therapy. <i>World Journal of Gastroenterology</i> , 2018 , 24, 2095-2107	5.6	10

248	HDV evolution-will viral resistance be an issue in HDV infection?. <i>Current Opinion in Virology</i> , 2018 , 32, 100-107	7.5	1
247	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 597-608	0.9	10
246	Healthcare value of implementing hepatitis C screening in the adult general population in Spain. <i>PLoS ONE</i> , 2018 , 13, e0208036	3.7	19
245	Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus. <i>BMC Infectious Diseases</i> , 2018 , 18, 446	4	19
244	Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant. <i>Infection and Drug Resistance</i> , 2018 , 11, 2207-2210	4.2	20
243	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 597-608	0.1	
242	Thrombotic thrombocytopenic purpura relapse induced by acute hepatitis E transmitted by cryosupernatant plasma and successfully controlled with ribavirin. <i>Transfusion</i> , 2018 , 58, 2501-2505	2.9	8
241	The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 999-1030	3.8	16
240	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. <i>Gastroenterology</i> , 2018 , 155, 1120-1127.e4	13.3	47
239	Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 784-793	4	48
238	Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 945-949.e1	6.9	18
237	Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBSAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. <i>Gut</i> , 2017 , 66, 2013-2023	19.2	34
236	Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 750-758	3.4	8
235	Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System. <i>Medicina Clínica</i> , 2017 , 148, 277-282	1.82	23
234	Hepatitis C virus infection. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17006	51.1	224
233	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. <i>Hepatology</i> , 2017 , 65, 1810-1822	11.2	64
232	Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1087-1094.e2	6.9	12
231	Successful Continuation of HCV Treatment After Liver Transplantation. <i>Transplantation</i> , 2017 , 101, 1009-1012	1.5	5

230	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. <i>Journal of Hepatology</i> , 2017 , 67, 370-398	13.4	2354
229	The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis. <i>Transplantation</i> , 2017 , 101, 987-995	1.8	16
228	Late presentation of chronic viral hepatitis for medical care: a consensus definition. <i>BMC Medicine</i> , 2017 , 15, 92	11.4	28
227	Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 468-475	6.1	26
226	Hepatitis C virus genotype 4: Genotype 1's little brother. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 4-12	3.4	3
225	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017 , 66, 1444-1453	11.2	180
224	A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN- γ induction. <i>Journal of Hepatology</i> , 2017 , 67, 669-679	13.4	31
223	Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System. <i>Medicina Clínica (English Edition)</i> , 2017 , 148, 277-282	0.3	1
222	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 325-336	18.8	153
221	Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus genotype. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 860-867	9.5	33
220	Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 904-916	3.4	7
219	Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 304-311	3.4	33
218	Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing. <i>Journal of Clinical Microbiology</i> , 2017 , 55, 504-509	9.7	15
217	Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. <i>PLoS ONE</i> , 2017 , 12, e0184550	3.7	32
216	Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. <i>PLoS ONE</i> , 2017 , 12, e0168713	3.7	6
215	Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 814-823	18.8	12
214	Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice. <i>Scientific Reports</i> , 2017 , 7, 3757	4.9	33
213	Red blood cell transfusion-transmitted acute hepatitis E in an immunocompetent subject in Europe: a case report. <i>Transfusion</i> , 2017 , 57, 244-247	2.9	30

212	No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 68-74	3.4	77
211	Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. <i>Gastroenterology</i> , 2017 , 152, 164-175.e4	13.3	136
210	Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection. <i>Journal of Infectious Diseases</i> , 2017 , 216, S792-S796	7	14
209	Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B. <i>Annals of Hepatology</i> , 2017 , 16, 358-365	3.1	3
208	A Case Report of Hepatocellular Carcinoma 5 Years After HBsAg Loss in Chronic Hepatitis Delta: How Long Surveillance is Required?. <i>Annals of Hepatology</i> , 2017 , 16, 630-632	3.1	0
207	Identification of sapovirus GV.2, astrovirus VA3 and novel anelloviruses in serum from patients with acute hepatitis of unknown aetiology. <i>PLoS ONE</i> , 2017 , 12, e0185911	3.7	9
206	Cost-effectiveness of a hepatitis B virus screening strategy to prevent reactivation in patients with hematologic neoplasms. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017 , 109, 619-626	0.9	4
205	Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B. <i>Annals of Hepatology</i> , 2017 , 16, 358-365	3.1	1
204	Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. <i>Clinical Infectious Diseases</i> , 2016 , 62, 32-6	11.6	85
203	Combination of Tenofovir Disoproxil Fumarate and Peginterferon α 2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2016 , 150, 134-144.e10	13.3	219
202	Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50, 779-89	3	20
201	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases</i> , 2016 , 16, 685-697	25.5	346
200	PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. <i>Journal of Hepatology</i> , 2016 , 64, 800-6	13.4	227
199	Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2016 , 64, 773-80	13.4	169
198	Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. <i>Journal of Hepatology</i> , 2016 , 64, 292-300	13.4	34
197	Ribavirin concentration determines treatment success of first-generation DAA-based chronic HCV therapy. <i>Antiviral Therapy</i> , 2016 , 21, 153-9	1.6	5
196	An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1). <i>PLoS ONE</i> , 2016 , 11, e0158526	3.7	3
195	Evidence of an Exponential Decay Pattern of the Hepatitis Delta Virus Evolution Rate and Fluctuations in Quasispecies Complexity in Long-Term Studies of Chronic Delta Infection. <i>PLoS ONE</i> , 2016 , 11, e0158557	3.7	14

194	New real-time-PCR method to identify single point mutations in hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2016 , 22, 9604-9612	5.6	5
193	HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection. <i>Clinical and Experimental Gastroenterology</i> , 2016 , 9, 351-363	3.1	3
192	Management of direct antiviral agent failures. <i>Clinical and Molecular Hepatology</i> , 2016 , 22, 432-438	6.9	30
191	Baseline HCV-RNA levels in genotype 1 chronic hepatitis C patients: The role of different cut-off points. <i>Hepatology</i> , 2016 , 64, 1385-6	11.2	1
190	Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 217-26	3.4	40
189	Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 923-6	2.2	1
188	Flares during long-term entecavir therapy in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1882-1887	4	7
187	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 196-206	18.8	259
186	Patient experience in HCV therapy: what really matters. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 90-92	18.8	3
185	Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 957-966	6.1	28
184	Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis. <i>Gastroenterology & Hepatology (English Edition)</i> , 2016 , 39, 449-457	0.1	
183	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. <i>Gut</i> , 2015 , 64, 1289-95	19.2	146
182	Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 260-8	4	23
181	Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. <i>Journal of Clinical Virology</i> , 2015 , 68, 56-60	14.5	9
180	Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. <i>Journal of Hepatology</i> , 2015 , 63, 564-72	13.4	123
179	Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?. <i>Journal of Clinical Virology</i> , 2015 , 68, 61-8	14.5	13
178	The potential role of simeprevir for the treatment of hepatitis C. <i>Future Virology</i> , 2015 , 10, 67-75	2.4	
177	Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection. <i>Genes and Immunity</i> , 2015 , 16, 297-300	4.4	8

176	Phylogenetic demonstration of hepatitis E infection transmitted by pork meat ingestion. <i>Journal of Clinical Gastroenterology</i> , 2015 , 49, 165-8	3	68
175	Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. <i>Hepatology International</i> , 2015 , 9, 243-50	8.8	46
174	Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. <i>European Journal of Gastroenterology and Hepatology</i> , 2015 , 27, 46-54	2.2	4
173	Management of direct-acting antiviral agent failures. <i>Journal of Hepatology</i> , 2015 , 63, 1511-22	13.4	62
172	Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 596-606	3.4	18
171	Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study. <i>Liver International</i> , 2015 , 35, 417-21	7.9	17
170	High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 219-26	9.7	64
169	Hepatitis C virus genotype 3: a genotype that is not easy-to-treat. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 375-85	4.2	14
168	Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. <i>Liver International</i> , 2015 , 35, 90-100	7.9	12
167	Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). <i>Antiviral Therapy</i> , 2015 , 21, 195-205	1.6	15
166	Therapy for hepatitis C genotype 3: moving forward. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 683-90	3.4	11
165	Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin. <i>Transplant Infectious Disease</i> , 2015 , 17, 208-20	2.7	8
164	Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. <i>Cancer</i> , 2015 , 121, 3631-8	6.4	125
163	Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load ($\geq 10^8$ log ₁₀ copies/ml). <i>Liver International</i> , 2015 , 35, 422-8	7.9	5
162	Hepatitis B e antigen status and hepatitis B DNA levels in women of childbearing age with chronic hepatitis B infection screening for clinical trials. <i>PLoS ONE</i> , 2015 , 10, e0121632	3.7	12
161	Complex Genotype Mixtures Analyzed by Deep Sequencing in Two Different Regions of Hepatitis B Virus. <i>PLoS ONE</i> , 2015 , 10, e0144816	3.7	8
160	Hepatitis B Virus Infection and the Kidney: Renal Abnormalities in HBV Patients, Antiviral Drugs Handling, and Specific Follow-Up 2015 , 2015, 1-11		10
159	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , 2015 , 14, 477-486	3.1	1

158	An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 1264-9	9.7	12
157	Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 1457-64	4	196
156	Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1282-91	5.9	9
155	Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Journal of Hepatology</i> , 2015 , 62, 363-70	13.4	124
154	ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. <i>PLoS ONE</i> , 2015 , 10, e0144004	3.7	5
153	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , 2015 , 14, 477-86	3.1	
152	Profiles and clinical management of hepatitis C patients in Spain: disHCovery study. <i>Revista Espanola De Quimioterapia</i> , 2015 , 28, 145-53	1.6	11
151	Development and evaluation of a baseline-event-anticipation score for hepatitis delta. <i>Journal of Viral Hepatitis</i> , 2014 , 21, e154-63	3.4	35
150	Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. <i>New England Journal of Medicine</i> , 2014 , 370, 1889-98	59.2	1402
149	Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. <i>Journal of Hepatology</i> , 2014 , 61, 1228-37	13.4	70
148	Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1064-71	11.6	31
147	Natural history and management of hepatitis C: does sex play a role?. <i>Journal of Infectious Diseases</i> , 2014 , 209 Suppl 3, S81-5	7	79
146	Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2014 , 384, 414-26	40	326
145	Clinical application of estimating hepatitis B virus quasispecies complexity by massive sequencing: correlation between natural evolution and on-treatment evolution. <i>PLoS ONE</i> , 2014 , 9, e112306	3.7	24
144	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , 2014 , 13, 356-363	3.1	15
143	Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE study. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 835-42	3.4	4
142	Optimal Management of HCV Genotype 3. <i>Current Hepatology Reports</i> , 2014 , 13, 279-285	1	
141	Relevance of a full-length genomic RNA standard and a thermal-shock step for optimal hepatitis delta virus quantification. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 3334-8	9.7	11

140	HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?. <i>Liver International</i> , 2014 , 34 Suppl 1, 108-11	7.9	17
139	Boceprevir plus peginterferon α 2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response. <i>Journal of Clinical Gastroenterology</i> , 2014 , 48, 435-43	3	2
138	Telbivudine improves renal function in patients with chronic hepatitis B. <i>Gastroenterology</i> , 2014 , 146, 138-146.e5	13.3	90
137	Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. <i>Gastroenterology</i> , 2014 , 146, 744-753.e3	13.3	37
136	Study of hepatitis B virus quasispecies by ultra-deep pyrosequencing: Resolving the nitty-gritty. <i>Hepatology</i> , 2014 , 59, 1210-2	11.2	1
135	Cirrhosis, liver transplantation and HIV infection are risk factors associated with hepatitis E virus infection. <i>PLoS ONE</i> , 2014 , 9, e103028	3.7	33
134	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , 2014 , 13, 356-63	3.1	12
133	Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. <i>Liver Transplantation</i> , 2013 , 19, 887-95	4.5	40
132	Faldaprevir and deleobuvir for HCV genotype 1 infection. <i>New England Journal of Medicine</i> , 2013 , 369, 630-9	59.2	198
131	Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. <i>Journal of Hepatology</i> , 2013 , 58, 792-800	13.4	88
130	A comparative study of ultra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies using hepatitis B virus infection as a model. <i>Antiviral Research</i> , 2013 , 98, 273-83	10.8	45
129	Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. <i>Hepatology</i> , 2013 , 58, 1918-29	11.2	233
128	Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review. <i>Pharmacoeconomics</i> , 2013 , 31, 63-75	4.4	13
127	Preparing the patient for success: treat or wait?. <i>Digestive and Liver Disease</i> , 2013 , 45 Suppl 5, S332-6	3.3	1
126	Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. <i>Lancet, The</i> , 2013 , 381, 468-75	40	1128
125	Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. <i>Gut</i> , 2013 , 62, 760-5	19.2	132
124	Hepatitis E virus: new faces of an old infection. <i>Annals of Hepatology</i> , 2013 , 12, 861-870	3.1	22
123	Molecular epidemiology and putative origin of hepatitis C virus in random volunteers from Argentina. <i>World Journal of Gastroenterology</i> , 2013 , 19, 5813-27	5.6	15

122	Quasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approach. <i>World Journal of Gastroenterology</i> , 2013 , 19, 6995-7023	5.6	31
121	Hepatitis E virus: new faces of an old infection. <i>Annals of Hepatology</i> , 2013 , 12, 861-70	3.1	10
120	HIV, HEV and cirrhosis: evidence of a possible link from eastern Spain. <i>HIV Medicine</i> , 2012 , 13, 379-83	2.7	40
119	Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. <i>Journal of Hepatology</i> , 2012 , 56, 520-6	13.4	107
118	EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2012 , 57, 167-85	13.4	2480
117	Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. <i>Journal of Hepatology</i> , 2012 , 57, 953-9	13.4	59
116	Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012 , 6, 683-93; quiz 694	4.2	18
115	Predicted effects of treatment for HCV infection vary among European countries. <i>Gastroenterology</i> , 2012 , 143, 974-85.e14	13.3	98
114	Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2012 , 26, 445-53	2.5	12
113	Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012 , 6, 413-21	4.2	10
112	Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. <i>PLoS ONE</i> , 2012 , 7, e37874	3.7	48
111	Efficacy and safety of entecavir in clinical practice in treatment-naïve Caucasian chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 535-42	2.2	21
110	Quasispecies dynamics in main core epitopes of hepatitis B virus by ultra-deep-pyrosequencing. <i>World Journal of Gastroenterology</i> , 2012 , 18, 6096-105	5.6	14
109	Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. <i>Gastroenterology</i> , 2011 , 140, 132-43	13.3	364
108	1990-2010: two decades of interferon-based therapy. <i>Clinics in Liver Disease</i> , 2011 , 15, 473-82	4.6	8
107	Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues?. <i>Annals of Hepatology</i> , 2011 , 10, 180-187	3.1	17
106	Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 434-42	3.4	92
105	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. <i>Liver International</i> , 2011 , 31 Suppl 2, 30-60	7.9	293

104	Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. <i>Antiviral Research</i> , 2011 , 92, 90-5	10.8	22
103	Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series. <i>BMC Gastroenterology</i> , 2011 , 11, 80	3	37
102	Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. <i>Hepatology</i> , 2011 , 53, 62-72	11.2	242
101	Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. <i>Hepatology</i> , 2011 , 54, 443-51	11.2	132
100	Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. <i>Hepatology</i> , 2011 , 54, 789-800	11.2	51
99	Ultra-deep pyrosequencing analysis of the hepatitis B virus preCore region and main catalytic motif of the viral polymerase in the same viral genome. <i>Nucleic Acids Research</i> , 2011 , 39, 8457-71	20.1	40
98	HBV core region variability: effect of antiviral treatments on main epitopic regions. <i>Antiviral Therapy</i> , 2011 , 16, 37-49	1.6	11
97	Infrequent detection of hepatitis E virus RNA in pregnant women with hepatitis E virus antibodies in Spain. <i>Liver International</i> , 2010 , 30, 1549-51	7.9	3
96	Main mutations in the hepatitis B virus basic core promoter (A1762T/G1764A) before HBeAg loss are markers that identify patients who will require long-term treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 97-104	6.1	5
95	New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents. <i>Infection and Drug Resistance</i> , 2010 , 3, 133-45	4.2	3
94	Analysis of the evolution in the circulation of HAV and HEV in eastern Spain by testing urban sewage samples. <i>Journal of Water and Health</i> , 2010 , 8, 346-54	2.2	51
93	Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. <i>Journal of Hepatology</i> , 2010 , 52, 658-64	12.4	118
92	Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2010 , 52, 493-500	13.4	96
91	Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. <i>Hepatology</i> , 2010 , 52, 1201-7	11.2	57
90	Reply:. <i>Hepatology</i> , 2010 , 52, 1520-1521	11.2	
89	Are recipients of solid organ transplantation a high-risk population for hepatitis E virus infection?. <i>Liver Transplantation</i> , 2010 , 16, 106-7; author reply 108	4.5	25
88	Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients. <i>American Journal of Gastroenterology</i> , 2009 , 104, 2449-57	9.7	21
87	Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy. <i>Journal of Clinical Microbiology</i> , 2009 , 47, 485-8	9.7	9

86	Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. <i>European Journal of Internal Medicine</i> , 2009 , 20, 478-81	3.9	7
85	Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. <i>Journal of Hepatology</i> , 2009 , 51, 11-20	13.4	168
84	Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2009 , 51, 640-6	13.4	62
83	Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. <i>Journal of Hepatology</i> , 2009 , 51, 1091-6	13.4	32
82	Some oral antivirals are more cost-effective than others for the treatment of chronic hepatitis B. <i>Journal of Hepatology</i> , 2009 , 51, 1087-1088	13.4	
81	Prevention of HBV recurrence after liver transplant: The role of combination therapy. <i>Digestive and Liver Disease Supplements</i> , 2009 , 3, 98-103		
80	Pharmacokinetics of intramuscular and intravenous HBIG: Which implications for practice?. <i>Digestive and Liver Disease Supplements</i> , 2009 , 3, 119-123		
79	Current trends in chronic hepatitis B management: results of a questionnaire. <i>European Journal of Gastroenterology and Hepatology</i> , 2009 , 21, 1177-83	2.2	5
78	Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfecting patients as a function of baseline CD4+ T-cell counts. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 52, 452-8	3.1	20
77	The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. <i>Genome Research</i> , 2009 , 19, 438-51	9.7	201
76	Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. <i>New England Journal of Medicine</i> , 2008 , 359, 2442-55	59.2	897
75	Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy. <i>Journal of Hepatology</i> , 2008 , 49, 695-701	13.4	33
74	Prevalence of hepatitis E virus infection in children in the northeast of Spain. <i>Vaccine Journal</i> , 2008 , 15, 732-4		28
73	Is telbivudine superior to lamivudine for the treatment of patients with chronic hepatitis B?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008 , 5, 494-5		2
72	Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain. <i>European Journal of Gastroenterology and Hepatology</i> , 2008 , 20, 320-6	2.2	17
71	De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection. <i>International Urology and Nephrology</i> , 2008 , 40, 539-41	2.3	9
70	Genotyping of hepatitis B virus--genotypes a to g by multiplex polymerase chain reaction. <i>Intervirology</i> , 2008 , 51, 247-52	2.5	16
69	Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response. <i>Antiviral Therapy</i> , 2008 , 13, 991-9	1.6	5

68	Adefovir for Chronic Hepatitis B Treatment: Identification of Virological Markers Linked to Therapy Response. <i>Antiviral Therapy</i> , 2008 , 13, 991-999	1.6	8
67	Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. <i>Hepatology</i> , 2007 , 46, 388-94	11.2	87
66	Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues. <i>Journal of Medical Virology</i> , 2007 , 79, 1671-3	19.7	3
65	Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naïve patients. <i>Journal of Viral Hepatitis</i> , 2007 , 14, 835-40	3.4	37
64	Evaluating the cost of sustained virologic response in naïve chronic hepatitis C patients treated with lamivudine. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 705-16	6.1	9
63	Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients. <i>Aids</i> , 2007 , 21, 477-81	3.5	25
62	Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. <i>Transplantation</i> , 2007 , 84, 650-4	1.8	81
61	Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2007 , 47, 366-72	13.4	70
60	Adefovir for lamivudine resistant HBV: More than meets the eye [Reply]. <i>Journal of Hepatology</i> , 2007 , 47, 619-620	13.4	1
59	Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients. <i>Liver Transplantation</i> , 2006 , 12, 1489-95	4.5	21
58	Community-based seroepidemiological survey of hepatitis E virus infection in Catalonia, Spain. <i>Vaccine Journal</i> , 2006 , 13, 1328-32		62
57	Simultaneous quantification and genotyping of hepatitis B virus for genotypes A to G by real-time PCR and two-step melting curve analysis. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 4491-7	9.7	27
56	Chronic hepatitis B: a critical appraisal of current approaches to therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 233-48	6.9	26
55	Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. <i>Journal of Hepatology</i> , 2006 , 44, 97-103	13.4	356
54	Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients. <i>Journal of Hepatology</i> , 2006 , 44, S60-4	13.4	8
53	Prevention and treatment of hepatitis B virus recurrence after liver transplantation. <i>Current Opinion in Organ Transplantation</i> , 2006 , 11, 589-593	2.5	
52	Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 23, 409-19	6.1	14
51	Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypes. <i>Journal of Clinical Virology</i> , 2005 , 34 Suppl 1, S79-82	14.5	38

50	Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1. <i>Pharmacoeconomics</i> , 2005 , 23, 1043-55	4.4	15
49	Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. <i>Journal of Hepatology</i> , 2005 , 42, 639-45	13.4	83
48	Drugs in development for hepatitis B. <i>Drugs</i> , 2005 , 65, 1451-60	12.1	19
47	Usefulness of dried blood samples for quantification and molecular characterization of HBV-DNA. <i>Hepatology</i> , 2004 , 40, 133-9	11.2	37
46	The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment. <i>Journal of Medical Virology</i> , 2004 , 73, 392-6	19.7	17
45	Mutations in the basic core promoter region of hepatitis B virus. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers. <i>Journal of Hepatology</i> , 2004 , 40, 507-14	13.4	41
44	Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin. <i>Journal of Hepatology</i> , 2004 , 40, 527-32	13.4	22
43	Sporadic cases of acute autochthonous hepatitis E in Spain. <i>Journal of Hepatology</i> , 2004 , 41, 126-31	13.4	68
42	Hepatitis E virus epidemiology in industrialized countries. <i>Emerging Infectious Diseases</i> , 2003 , 9, 448-54	10.2	216
41	Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. <i>Hepatology</i> , 2003 , 37, 1226-7	11.2	48
40	A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIG) and lamivudine with long-term lamivudine plus HBIG in the prevention of hepatitis B virus recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2003 , 38, 811-7	13.4	148
39	Current therapies for chronic hepatitis B. <i>Annals of Hepatology</i> , 2003 , 2, 108-12	3.1	
38	Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. <i>Hepatology</i> , 2002 , 35, 930-6	11.2	91
37	Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?. <i>Journal of Hepatology</i> , 2002 , 36, 445-6	13.4	55
36	Which is the Most Cost-Effective Combination Therapy Strategy Using Interferon α 2b plus Ribavirin for Naïve Patients with Chronic Hepatitis C?. <i>Clinical Drug Investigation</i> , 2002 , 22, 31-39	3.2	7
35	High-Dose interferon-alpha2b plus ribavirin for retreatment of interferon-nonresponsive patients infected with genotype 1 hepatitis C virus. <i>Digestive Diseases and Sciences</i> , 2001 , 46, 2396-400	4	3
34	Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. <i>Hepatology</i> , 2001 , 34, 404-10	11.2	179
33	Genetic analysis of hepatitis A virus strains recovered from the environment and from patients with acute hepatitis. <i>Journal of General Virology</i> , 2001 , 82, 2955-2963	4.9	67

32	Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B. <i>Journal of Infectious Diseases</i> , 2001 , 183, 1277-80	7	23
31	Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , 2000 , 45, 685-9	4	8
30	Cost-effectiveness of combination therapy for naïve patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2000 , 33, 651-658	13.4	23
29	Rapid screening of the Cys282Tyr and His63Asp mutations in the HFE gene. <i>Journal of Hepatology</i> , 2000 , 32, 362-3	13.4	3
28	HEV identified in serum from humans with acute hepatitis and in sewage of animal origin in Spain. <i>Journal of Hepatology</i> , 2000 , 33, 826-33	13.4	190
27	Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2000 , 33, 651-8	13.4	55
26	Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation. <i>Liver International</i> , 1999 , 19, 177-82	7.9	39
25	Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. <i>Journal of Virological Methods</i> , 1999 , 83, 181-7	2.6	43
24	Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. <i>Hepatology</i> , 1999 , 29, 889-96	11.2	429
23	Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. <i>Journal of Hepatology</i> , 1998 , 28, 510-3	13.4	31
22	Hepatitis delta genotypes in chronic delta infection in the northeast of Spain (Catalonia). <i>Journal of Hepatology</i> , 1998 , 28, 971-7	13.4	18
21	The value of quantitative detection of HBV-DNA amplified by PCR in the study of hepatitis B infection. <i>Journal of Hepatology</i> , 1996 , 24, 680-5	13.4	38
20	Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections?. <i>Journal of Medical Virology</i> , 1996 , 49, 66-9	19.7	25
19	Interferon vs. adenine arabinoside 5Monophosphate in patients with anti-HBe-positive chronic hepatitis. <i>Journal of Medical Virology</i> , 1996 , 49, 325-8	19.7	2
18	Hepatitis E virus infection in acute hepatitis in Spain. <i>Journal of Virological Methods</i> , 1995 , 55, 49-54	2.6	31
17	Determination of hepatitis delta virus RNA by polymerase chain reaction in acute and chronic delta infection. <i>Hepatology</i> , 1995 , 21, 25-29	11.2	16
16	Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. <i>Hepatology</i> , 1995 , 22, 1641-7	11.2	165
15	Comparative analysis of serological markers of chronic delta infection: HDV-RNA, serum HDAg and anti-HD IgM. <i>Journal of Virological Methods</i> , 1994 , 50, 59-66	2.6	11

14	Etiology of acute sporadic hepatitis in Spain: the role of hepatitis C and E viruses. <i>Journal of Hepatology</i> , 1994 , 20, 589-92	13.4	21
13	Detection of hepatitis B precore mutants by the fluorescent linear polymerase chain reaction sequencing method. <i>Journal of Hepatology</i> , 1994 , 21, 934-9	13.4	6
12	Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. <i>American Journal of Nephrology</i> , 1992 , 12, 144-7	4.6	93
11	Clinical significance of two forms of IgM antibody to hepatitis delta virus. <i>Hepatology</i> , 1991 , 14, 25-8	11.2	13
10	The presence of anti-HCV antibodies in the serum of patients with chronic active hepatitis and antinuclear antibodies. <i>Hepatology</i> , 1990 , 11, 333-5	11.2	6
9	Hepatitis B virus and hepatitis D virus replication in HBsAg-positive fulminant hepatitis. <i>Hepatology</i> , 1990 , 11, 1062-5	11.2	14
8	Chronic delta hepatitis: detection of hepatitis delta virus antigen in serum by immunoblot and correlation with other markers of delta viral replication. <i>Hepatology</i> , 1989 , 10, 907-10	11.2	26
7	Serological profile of tissue autoantibodies during acute and chronic delta hepatitis. <i>Journal of Hepatology</i> , 1989 , 9, 345-50	13.4	12
6	Hepatitis D virus RNA in acute delta infection: serological profile and correlation with other markers of hepatitis D virus infection. <i>Hepatology</i> , 1988 , 8, 1125-9	11.2	33
5	Anti-HD IgM as a marker of chronic delta infection. <i>Journal of Hepatology</i> , 1987 , 4, 62-5	13.4	21
4	Clinical and serological outcome of acute delta infection. <i>Journal of Hepatology</i> , 1987 , 5, 59-64	13.4	14
3	Serological diagnosis of acute delta hepatitis. <i>Journal of Medical Virology</i> , 1986 , 18, 81-5	19.7	39
2	Delta agent in nondrug addicts. <i>Hepatology</i> , 1985 , 5, 526-8	11.2	
1	Amino acid substitutions associated with treatment failure of hepatitis C virus infection		1